DSP commits to cell therapy, regen medicine as R&D pillar | PharmaBoardroom
written on 06.03.2014
Tags:
,

DSP commits to cell therapy, regen medicine as R&D pillar

TAGS: ,

Dainippon Sumitomo Pharma (DSP) has signaled its intention to position cell therapy and regenerative medicine, along with vaccines, as a major new pillar of its R&D strategy, in parallel with a continued focus on the firm's main strategic areas of…

Latest Report